Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study

BACKGROUND: The incidence of bone metastases in non-small cell lung cancer (NSCLC) patients is about 30–40% and bone-related events can seriously affect quality of life. Immune checkpoint inhibitor (ICI) therapy has become the standard treatment for advanced NSCLC patients. However, the specific eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiang, Huiping, Lei, Yuqiong, Shen, Yinchen, Li, Jiaqi, Zhong, Hua, Zhong, Runbo, Zhang, Xueyan, Chang, Qing, Lu, Jiahuan, Feng, Hui, Zhu, Yan, Addeo, Alfredo, Banna, Giuseppe L., Oh, In-Jae, Qian, Jialin, Chu, Tianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825649/
https://www.ncbi.nlm.nih.gov/pubmed/35242630
http://dx.doi.org/10.21037/tlcr-21-1033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825649/
https://www.ncbi.nlm.nih.gov/pubmed/35242630
http://dx.doi.org/10.21037/tlcr-21-1033

Ejemplares similares